Shwachman-Diamond Syndrome Alliance Inc.
Woburn, Massachusetts, 01888, United States
Location status: Recruiting
Location contact
Eszter Hars, Ph.D.
CONTACT
Eszter Hars, Ph.D.
PRINCIPAL_INVESTIGATOR
SDS-GPS Program Team
CONTACT
NCT Number: NCT06999954
The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to
* expand the understanding of SDS * improve the lives of people with SDS, and * accelerate the development of new therapies and cures for SDS.
By joining, participants will receive early access to relevant information about new clinical trials and other research opportunities (such as clinical registries) based on their profile, accelerating research and increasing clinical trial impact and recruitment success.
The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.
Interested in participating?
Request InfoAll sexes
Observational
Woburn, Massachusetts, 01888, United States
Location status: Recruiting
Eszter Hars, Ph.D.
CONTACT
Eszter Hars, Ph.D.
PRINCIPAL_INVESTIGATOR
SDS-GPS Program Team
CONTACT
What is SDS-GPS?
The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, with the goal of
SDS-GPS was created for the patients, by the patients, with thoughtful input from patients, families, advocates, caregivers, researchers, clinicians, and regulators.
Participants will be part of a global community that cares, turns hope into action, and drives research. Participants' experience - whether it falls in the mild or severe end of the spectrum - matters. Their voice counts.
How can patients' stories help drive therapies and cures?
Participants' stories help paint a more complete picture of what SDS is and how it impacts the people living with it. Their participation helps build a strong, engaged community, which is critical to drive progress. Without patients and their families, research cannot advance.
The investigators (the SDS-GPS team at the SDS Alliance) use participants' de-identified aggregate survey responses and other data they share to develop a deeper understanding of the unmet needs of the community.
The investigators use the insights to
What aspects of their story can participants share through SDS-GPS?
Surveys on the SDS-GPS Program Platform are designed to be quick and easy, without the need to have to look up any details from medical records. They can save their progress and come back anytime.
Survey topics include:
How does SDS-GPS work?
The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The Program invites patients of all ages who have a confirmed diagnosis of the below, using established diagnostic guidelines, plus their parents/caregivers.
Exclusion criteria
● People who do not meet the above criteria.
Time frame: At baseline and every 12 months, prospectively.
Patients report symptoms via surveys, grouped by organ system.
Time frame: Through study completion when the genetics report is available.
Clinical genetics reports are uploaded by the patient (or caregiver) and curated by study staff to confirm a genetic diagnosis, understand variants, and assess the use of appropriate genetic testing methodologies.
Time frame: Through study completion, an average of 2-4 times per year.
PROMIS surveys in various domains, such as fatigue, pain, anxiety, and depression, are administered as surveys and scored with the standard PROMIS scoring methods.
Specific PROMIS measures to include:
v1.0 Anxiety 8a short form v1.0 Depression 8a short form v1.0 Pain Interference 6a short form v2.0 Cognitive Function 8a short form v1.0 Self-Efficacy for Managing Chronic Conditions: Manage Daily Activities 8a short form v1.0 - Self-Efficacy for Managing Symptoms 8a v2.0 Satisfaction Social Roles and Activities 8a short form v2.0 Ability to Part Social Roles and Activities 8a short form v2.0 Social Isolation 8a short form v1.0 Fatigue 13a short form (FACIT-Fatigue)
v3.0 PP: Depressive Symptoms 6a short form v3.0 PP: Fatigue 10a short form v3.0 PP: Mobility 7a short form v3.0 PP: Pain Interference 8a short form v1.0 PP: Cognitive Function 7a short form
Time frame: At baseline and every 12 months, prospectively.
Patients fill out surveys to report on disease burden (such as number and duration of hospitalizations), treatment burden (such as surveillance), and treatment outcomes (such as HSC transplant outcomes)
Contact information is provided by the study sponsor or research team.
Eszter Hars, Ph.D.
CONTACT
SDS-GPS Program Team
CONTACT
Shwachman-Diamond Syndrome Alliance Inc
Other
The Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Program (SDS-GPS Program)
Acronym: SDS-GPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01529827
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Buffalo, New York, United States
View Trial DetailsNCT00499070
Anemia, Anemia, Aplastic
Vienna, Austria
View Trial DetailsNCT06056908
Agranulocytosis, Bone Marrow Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial Details